Breast Cancer Clinical Trials

• Adult female or male participants.

• ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.

• Evaluable disease (measurable disease per RECIST 1.1 or bone-only disease).

• De novo advanced breast cancer or with disease recurrence occurring after 12 months of completing adjuvant endocrine therapy (with or without CDK4/6 inhibitors)

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate hematologic, hepatic, and renal functions.

• Female participants can be pre-, peri- or postmenopausal.

• Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.